Safety in Numbers

A few weeks ago I was interviewed by Bio-IT World magazine for an article about trends in drug safety.  The article generated a lot of interest from customers curious about SAS’ approach to safety and pharmacovigilence which is nice to see.  We have been making some investments in building out new capabilities in this area for a while, and I am encouraged to see the level of interest.

With both political parties needing an attack strategy around healthcare, the villianization of the pharmaceutical industry has only increased this year.  I think this is a real shame because the fundamental needs around improving drug development time, cost, and efficacy are masked in arguments over high drug prices and alleged safety cover-ups.  The sheer noise level is enough to make people wary of even discussing drug safety issues.  And there is the rub.

Continue reading “Safety in Numbers”

A few weeks ago I was interviewed by Bio-IT World magazine for an article about trends in drug safety.  The article generated a lot of interest from customers curious about SAS’ approach to safety and pharmacovigilence which is nice to see.  We have been making some investments in building out new capabilities in this area for a while, and I am encouraged to see the level of interest.

With both political parties needing an attack strategy around healthcare, the villianization of the pharmaceutical industry has only increased this year.  I think this is a real shame because the fundamental needs around improving drug development time, cost, and efficacy are masked in arguments over high drug prices and alleged safety cover-ups.  The sheer noise level is enough to make people wary of even discussing drug safety issues.  And there is the rub.

Continue reading “Safety in Numbers”

Link to original post